SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer.
Authors
Clamp, Andrew RMäenpää, J
Cruickshank, D
Ledermann, J A
Wilkinson, Peter M
Welch, Richard
Chan, S
Vasey, Paul
Sorbe, B
Hindley, A
Jayson, Gordon C
Affiliation
Cancer Research UK Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK.Issue Date
2006-01-16
Metadata
Show full item recordAbstract
The feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-weekly cycles of docetaxel 100 mg m(-2) (arm A, n=51) or docetaxel 60 mg m(-2) with irinotecan 200 mg m(-2) (arm B, n=49). Neither arm met the formal feasibility criterion of an eight-cycle treatment completion rate that was statistically greater than 60% (arm A 71% (90% confidence interval (CI) 58-81%; P=0.079; arm B 67% (90% CI 55-78%; P=0.184)). Median-dose intensities were >85% of planned dose for all agents. In arms A and B, 15.6 and 12.2% of patients, respectively, withdrew owing to treatment-related toxicity. Grade 3-4 sensory neurotoxicity was more common in arm A (1.9 vs 0%) and grade 3-4 diarrhoea was more common in arm B (0.6 vs 3.5%). Of patients with radiologically evaluable disease at baseline, 50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months' follow-up, median progression-free survival was 17.1 and 15.9 months, respectively. Although both arms just failed to meet the formal statistical feasibility criteria, the observed completion rates of around 70% were reasonable. The addition of irinotecan to first-line carboplatin and docetaxel chemotherapy was generally well tolerated although associated with increased gastrointestinal toxicity. Further exploratory studies of topoisomerase-I inhibitors in this setting may be warranted.Citation
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer. 2006, 94 (1):55-61 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/sj.bjc.6602910PubMed ID
16404360Type
ArticleLanguage
enISSN
0007-0920ae974a485f413a2113503eed53cd6c53
10.1038/sj.bjc.6602910
Scopus Count
Related articles
- SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
- Authors: Vasey PA, Atkinson R, Osborne R, Parkin D, Symonds R, Paul J, Lewsley L, Coleman R, Reed NS, Kaye S, Rustin GJ
- Issue date: 2006 Jan 16
- A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
- Authors: Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G
- Issue date: 2014 Dec 11
- Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.
- Authors: Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, Parkin D, Paul J, Hay A, Kaye SB, Scottish Gynaecological Cancer Trials Group
- Issue date: 2004 Nov 17
- Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
- Authors: Escobar PF, Markman M, Rose P, Zanotti K, Webster K, Belinson J
- Issue date: 2004 Jan
- A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
- Authors: Gould N, Sill MW, Mannel RS, Thaker PH, DiSilvestro PA, Waggoner SE, Yamada SD, Armstrong DK, Fracasso PM, Walker JL
- Issue date: 2012 Dec